Press Conference 3: Monday, 10 October

Moderator: Dirk Arnold

  • LBA9_PR: Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednison in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). Karim Fizazi
  • LBA11_PR: Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRACAlain Ravaud
  • LBA30_PR: CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. Toni Choueiri
  • LBA6_PR: Full-dose neoadjuvant anthracycline+ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial. Alessandro Gronchi